Join AlphaMaven

The Home Of Alternative Investments

Register For Free Learn More Create Investment Listing

Most Visited Alternative Investment Industry Website. Over 50,000 visitors per month

Alternative Investment Posts

Andrea Alms Video:  Money In Motion 86 - Stem Cell Market - Part 1
Private Equity BrookDell Partners Views: 4

TRANSCRIPT: Hello. My name is Andre and I am technology investor and financial manager and this is your money emotion. I was asked about mesenchymal stem cell market. What is it? STEM cells are specialized cells capable of renewing themselves through cell division and differentiate into multiple cell lines. The first clinical trial of MSC was completed by Auris Therapeutics in 1995.

The first regulatory approval of MSC was granted conditional approval in 2012, in Canada and New Zealand for


Member Posts:

Most popular| Most recent
AlphaMaven Crypto Traders Index
4d ago Crypto AlphaMaven Crypto Traders Index #Investment Update
AlphaMaven Cannabis Index
4d ago Cannabis AlphaMaven Cannabis Index #Investment Update
AlphaMaven Hedge Fund Index
4d ago Hedge Fund AlphaMaven Hedge Fund Index #Investment Update
ParaImbal, LP Investor Presentation - March 2025
3d ago Managed Futures Paraimbal #Presentation
ParaImbal, LP - AlphaMaven Performance Report
3d ago Managed Futures Paraimbal #Investment Update
Rome Capital Long Levered Strategy - AlphaMaven Performance Report
3d ago Hedge Fund Rome Capital Long Levered Strategy #Investment Update
Andrea Alms Video:  Money In Motion 153 - FDA Staff Cuts - Biotech Regulatory Delays M ...
3d ago Private Equity BrookDell Partners #Video
Andrea Alms Video:  Money In Motion 152 - Tariffs Pharma/Biotech Market Update
3d ago Private Equity BrookDell Partners #Video
Andrea Alms Video:  Money In Motion 151 - Ozempic Impact & GLP-1 Receptor Agonist Mark ...
3d ago Private Equity BrookDell Partners #Video
Andrea Alms Video:  Money In Motion 150 - Gene Therapy Adeno-Associated Virus (AAV)
3d ago Private Equity BrookDell Partners #Video
Andrea Alms Video:  Money In Motion 149 - Pediatric Rare Disease Market
3d ago Private Equity BrookDell Partners #Video
Robosig FX Alpha Gen Fund Posts Its March 2025 Results
3d ago Hedge Fund RoboSig FX Alpha Gen Fund #Investment Update
ARB Flagship Fund - AlphaMaven Performance Report
3d ago Hedge Fund ARB Flagship Fund #Investment Update
SBGM Futures Portfolio Strategy Performance Report
3d ago Managed Futures SBGM Futures Portfolio Strategy #Investment Update
AlphaMaven Managed Futures Index
4d ago Managed Futures AlphaMaven Managed Futures Index #Investment Update
AlphaMaven Real Estate Index
4d ago Real Estate AlphaMaven Real Estate Index #Investment Update
AlphaMaven Private Equity Index
4d ago Private Equity AlphaMaven Private Equity Index #Investment Update
AlphaMaven Venture Capital Index
4d ago Venture Capital AlphaMaven Venture Capital Index #Investment Update
Advanced Alpha Advisors Adjusted Risk Technology Strategy - AlphaMaven Performance Report
1w ago Managed Futures ART ( Adjusted Risk Technology) #Investment Update
Armington Capital Trading Program - AlphaMaven Performance Report
1w ago Managed Futures Armington Capital Trading Program #Investment Update
CREATE A FREE MEMBERSHIP
View Member Posts Listings
SPONSORED BY
Be Seen - Advertise With Us
Click to Discuss
FEATURED MEMBER POSTS
Andrea Alms Video:  Money In Motion 152 - Tariffs Pharma/Biotech Market Update
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 153 - FDA Staff Cuts - Biotech Regulatory Delays Market Update
- posted by: BrookDell Partners
Andrea Alms Video: Money In Motion 148 - Water Market
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 149 - Pediatric Rare Disease Market
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 151 - Ozempic Impact & GLP-1 Receptor Agonist Market Update
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 150 - Gene Therapy Adeno-Associated Virus (AAV)
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 147 - Pediatric Healthcare Market
- posted by: BrookDell Partners
Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates

Subscribe to our FREE DAILY newsletter

Please Select Industry Primary Role*
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
Sign Up Now
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.